Bayer sues Lupin over generic birth control pill

FRANKFURT Fri Nov 30, 2012 6:18am IST

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011. REUTERS/Fabrizio Bensch/Files

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch/Files

Related Topics

Stocks

   

FRANKFURT (Reuters) - German drugmaker Bayer (BAYGn.DE) has filed a lawsuit in the United States against Indian generic drug maker Lupin (LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia in the U.S.

In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.

The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sales of the generic product.

Lupin declined to comment on the lawsuit. "We do not comment on on-going litigations as a matter of policy," said Lupin spokesperson Shamsher Gorawara.

Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.

Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.

Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware. (Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle; editing by Carol Bishopric)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Monetary Policy

Monetary Policy

Fed renews zero rate pledge, but hints at steeper rate hike path.  Full Article 

Eyeing Stocks

Eyeing Stocks

Interview - EPFO chief urges green light to buy stocks  Full Article 

Stimulus Reports

Stimulus Reports

China cenbank injects $81 bln into major banks to support economy - reports  Full Article 

Ranbaxy Investigation

Ranbaxy Investigation

Ranbaxy says U.S. authorities seek information on pricing data.  Full Article 

E-Commerce

E-Commerce

Tiger Global leads $60 million investment in Quikr.  Full Article 

Monsoon Update

Monsoon Update

Delayed retreat of monsoon rains to start this weekend  Full Article 

Financing Deal

Financing Deal

IndiGo agrees $2.6 billion aircraft finance deal with China's ICBC  Full Article 

Grim Outlook

Grim Outlook

Sony deepens loss estimate on struggling smartphone business  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage